News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

Investigators Report Efficacy Trends With PHE885 in R/R Multiple Myeloma

June 4, 2023
Tony Berberabe, MPH
Article
Conference|ASCO Annual Meeting: Hematology

A phase 1 trial continued to show positive responses when PHE885 was used in patients with relapsed/refractory multiple myeloma.

A phase 1 trial continued to show positive responses when PHE885 was used in patients with relapsed/refractory multiple myeloma.

A phase 1 trial continued to show positive responses when PHE885 was used in patients with relapsed/refractory multiple myeloma.

Increased objective response rates (ORR), high minimal residual (MRD) negativity rates, and no new safety signals were observed when PHE885 was utilized in patients with relapsed/refractory multiple myeloma, according to results from a phase 1 trial (NCT04318327) presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

The CAR product was created using the T-Charge process, which led to significantly shortened production time. This is an important development because prolonged manufacturing time may limit patient access, especially in aggressive disease, according to Adam S. Sperling, MD, PhD, et al.

“Despite the approval of 2 CAR T products, there is a need for improved production with faster and more reliable manufacturing to generate products that provide prolonged clinical benefit for patients,” lead author Sperling, associate director of basic and correlative science, multiple myeloma, and cell therapies at the Dana-Farber Cancer Institute in Boston, Massachusetts.

Sperling presented updated data after a median follow-up of 6.7 months at the data cutoff of March 28, 2023. Investigators reported that the ORR was 100% at the active doses of 10 × 106 and 20 × 106. For all patients (N = 49), the ORR was 98% and a very good partial response of 80%.

PHE885 is an autologous, fully human, B-cell maturation antigen (BCMA)-directed CAR T-cell therapy. Overall, the advantages of the T-Charge process can result in a 2 day manufacturing time, preserve T-cell stemness, and enhance in vivo expansion. This can lead to a door-to-door time from leukapheresis to infusion of less than 10 days, according to Sperling.

“Because the cells spend a limited time ex vivo, the process preserves T-cell stemness, which we hope will enhance in vivo expansion, persistence, and T-cell function,” Sperling said.

When investigators analyzed PHE855 by flow cytometry in 41 patients, comparing apheresis and final product pairs, they noted no significant differences in percentage of central memory, effector memory, and T-cell subsets. In particular, there was a trend toward enriched CD4 central memory T-cells in the final product. This demonstrates a greater potential for in vivo expansion with longer persistence and improved function, said Sperling.

Patient median age was 65 years (range, 45-81) and 33% had extramedullary disease. Patients had undergone a median of 4 lines of prior therapy with 94% being triple refractory and 62% being penta refractory. Thirty-four percent of patients had received bridging therapy.

The CAR agent was administered at multiple dose levels ranging from 2.5 to 20 million cells on day 1 and following infusion, there was remarkable in vivo expansion with prolonged persistence of the agent. Investigators plotted the absolute lymphocyte count for patients with early time points demonstrating low lymphocyte counts, which likely reflected the recent exposure to lymphodepleting chemotherapy, said Sperling. With CAR T expansion, lymphocyte count increased, of which almost all were CD3-positive CAR-positive cells. “In some patients, we saw a dramatic expansion with white blood cell counts reaching 20,000 or greater and with almost all cells showing CD3-positive T cells,” Sperling said.

Simultaneous with expansion, investigators also reported high response rates, with all but 1 patient responding to treatment. This patient was treated with the lowest dose of 2.5 million cells. Sperling noted that at the time to receive lymphodepleting chemotherapy, the patient had progressed, with 20% of their white cells being plasma cells.

“I think a patient with this type of aggressive disease would probably not have made it to cell infusion [if they were given] a standard CAR product that had a 6 to 8 week manufacturing turnaround time,” Sperling said.

Investigators reported early responses, with a median time to first response of 0.95 months and a median time to best response of 2.76 months. At 3 months, patients who received the 20 × 106 dose exhibited an 80% response (n = 4/5) and at 6 months, the response was 100% (n = 3/3). At 3 months, patients who received the 10 × 106 dose had a 54% response (n = 7/13) and at 6 months, a 71% response (n = 5/7). Complete responses and stringent complete responses were observed as late as 18 months post-infusion.

The safety profile of PHE855 is similar to that seen in other CAR T-cell studies. Cytokine release syndrome (CRS) was common and was observed in all but 2 patients, but most cases were limited to grade 1 or grade 2. Time of onset for CRS was 8 days. Interventions administered to alleviate CRS, such as tocilizumab (Actemra), corticosteroids, and anakinra (Kineret), were common.

Neurotoxicity of any grade was seen in only 20% of patients, with most cases being grade 1 or 2. All occurred concurrently with CRS and resolved with treatment. There were no cases of delayed neurotoxicity or Parkinsonian-like features observed.

Other adverse events were similar to that seen in other CAR T-cell studies; the most common hematologic toxicities were elevations in aspartate aminotransferase, alanine transaminase, and amylase levels.

Dose-limiting toxicities were observed across all dose levels and in 33% of patients who received the highest dose of 20 × 106. At this dosage, neutropenia (grade 4), ejection fraction decrease (grade 3), atrial fibrillation (grade 3), and neurotoxicity (grade 3) were observed. Investigators reported that 13 patients died due to progressive disease, 1 patient died due to hemorrhagic shock that was determined to be unrelated to PHE855, and 1 patient died due to a lung infection attributed to the study drug.

“A phase 2 study of PHE855 is currently underway in patients with relapsed and refractory multiple myeloma and evaluation in earlier lines of therapy is set to begin,” concluded Sperling.

Reference

Sperling AS, Derman BA, Nikiforow S, et al. Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM). J Clin Oncol. 2023;41(suppl 16):8004. doi: 10.1200/JCO.2023.41.16_suppl.8004

Related Videos
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Experts on MM
Experts on MM
Experts on multiple myeloma
Experts on multiple myeloma
Experts on multiple myeloma
Experts on MM
Related Content

Teclistamab Produces Responses in Pretreated R/R Multiple Myeloma

October 2nd 2023

Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

August 14th 2023

Immunotherapy Sequences May Lead to Disease Resistance/Relapse in Myeloma

October 1st 2023

Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023

August 7th 2023

Daratumumab Combos Are Effective in NDMM Despite Relapses in Subgroups

September 29th 2023

Real-world Teclistamab Use Finds Comparable Efficacy With MajesTec-1 in Multiple Myeloma

September 29th 2023

Teclistamab Produces Responses in Pretreated R/R Multiple Myeloma

October 2nd 2023

Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

August 14th 2023

Immunotherapy Sequences May Lead to Disease Resistance/Relapse in Myeloma

October 1st 2023

Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023

August 7th 2023

Daratumumab Combos Are Effective in NDMM Despite Relapses in Subgroups

September 29th 2023

Real-world Teclistamab Use Finds Comparable Efficacy With MajesTec-1 in Multiple Myeloma

September 29th 2023

Teclistamab Produces Responses in Pretreated R/R Multiple Myeloma

October 2nd 2023

Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

August 14th 2023

Immunotherapy Sequences May Lead to Disease Resistance/Relapse in Myeloma

October 1st 2023

Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023

August 7th 2023

Daratumumab Combos Are Effective in NDMM Despite Relapses in Subgroups

September 29th 2023

Real-world Teclistamab Use Finds Comparable Efficacy With MajesTec-1 in Multiple Myeloma

September 29th 2023
Related Content
Advertisement

Data suggest a role for TIGIT blockade or CD25-positive cell depletion to enhance teclistamab’s efficacy in relapsed/refractory multiple myeloma.

Teclistamab Produces Responses in Pretreated R/R Multiple Myeloma

October 2nd 2023
Article

Data suggest a role for TIGIT blockade or CD25-positive cell depletion to enhance teclistamab’s efficacy in relapsed/refractory multiple myeloma.


Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

August 14th 2023
Podcast

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.


BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents.

Immunotherapy Sequences May Lead to Disease Resistance/Relapse in Myeloma

October 1st 2023
Article

BCMA and GPRC5D loss in patients with multiple myeloma may lead to resistance to continuous treatment with anti–BCMA and anti–GPRC5D agents.


Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.

Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023

August 7th 2023
Podcast

Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.


APOBEC mutational activity appears to be prognostic in patients with newly diagnosed multiple myeloma or precursor diseases who receive daratumumab quadruplets, according to Kylee Maclachlan, MBChB, PhD.

Daratumumab Combos Are Effective in NDMM Despite Relapses in Subgroups

September 29th 2023
Article

APOBEC mutational activity appears to be prognostic in patients with newly diagnosed multiple myeloma or precursor diseases who receive daratumumab quadruplets, according to Kylee Maclachlan, MBChB, PhD.


When teclistamab was evaluated in a real-world setting, investigators determined that efficacy was similar between that and the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.

Real-world Teclistamab Use Finds Comparable Efficacy With MajesTec-1 in Multiple Myeloma

September 29th 2023
Article

When teclistamab was evaluated in a real-world setting, investigators determined that efficacy was similar between that and the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.